Human Von Hippel Lindau Tumor Suppressor (vHL) RTU ELISA Kit | vHL rtu elisa kit

Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit

Cat. Num. AAA4503326

• Gene Names: VHL; RCA1; VHL1; pVHL; HRCA1
• Reactivity: Human
• Synonyms: Von Hippel Lindau Tumor Suppressor (vHL); Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Kit; HRCA1; RCA1; VHL1; Von Hippel-Lindau Syndrome; vHL rtu elisa kit

• Reactivity: Human
• Sequence Length: 213

• Assay Type: Sandwich
• Samples: Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates or Other Biological Fluids.
• Detection Range: 0.156-10ng/mL
• Sensitivity: 0.062ng/mL
• RTU ELISA Kit's Advantage: The Ready-To-Use (RTU) Kits require fewer steps in setup and take less time to run. Detection Solutions are pre-diluted and total incubation time is shorter than many other ELISA Kits.
• Preparation and Storage: For unopened kits: All the reagents should be kept at 4 degree C upon receipt.; For opened kits: Once the kit is opened, the remaining reagents still need to be stored according to the above storage conditions. In addition, return the unused wells to the foil pouch containing the desiccant pack and reseal along entire edge of zip-seal.

Typical Testing Data/Standard Curve (for reference only)

Related Product Information for vHL rtu elisa kit

Test Principle: The microtiter plate provided in this kit has been pre-coated with an antibody specific to vHL. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody preparation specific to vHL. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain vHL, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of vHL in the samples is then determined by comparing the O.D. of the samples to the standard curve.

NCBI and Uniprot Product Information

• NCBI GI #: 4507891
• NCBI GeneID: 7428
• NCBI Accession #: NP_000542.1
• NCBI GenBank Nucleotide #: NM_000551.3
• UniProt Accession #: P40337; Q13599; Q6PDA9; B2RE45
• Molecular Weight: 18,532 Da
• NCBI Official Full Name: von Hippel-Lindau disease tumor suppressor isoform 1
• NCBI Official Synonym Full Names: von Hippel-Lindau tumor suppressor
• NCBI Official Symbol: VHL
• NCBI Official Synonym Symbols: RCA1; VHL1; pVHL; HRCA1
• NCBI Protein Information: von Hippel-Lindau disease tumor suppressor
• UniProt Protein Name: von Hippel-Lindau disease tumor suppressor
• Protein Family: Von Hippel-Lindau disease tumor suppressor
• UniProt Gene Name: VHL

NCBI Description

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]

Uniprot Description

Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. Ubiquitinates, in an oxygen-responsive manner, ADRB2.